The first description of endothelial progenitor cells (EPC) in 1997 led rapidly to substantial
changes in our understanding of angiogenesis, and within 5 years to the first clinical studies …

Endothelial progenitor cells (EPCs) reside in the bone marrow and are mobilized into the
circulation by specific stimuli such as certain drugs, ischemia, and exercise training. Once in …

Recent studies suggest that circulating progenitor cells contribute to the formation of new
blood vessels in adults after tissue ischemia. The infusion of these progenitor cells was used …

Background—We compared the therapeutic potential of purified mobilized human CD34+
cells with that of mobilized total mononuclear cells (tMNCs) for the preservation/recovery of …

Background Endothelial progenitor cells derived from bone marrow are believed to support
the integrity of the vascular endothelium. The number and function of endothelial progenitor …

Background Endothelial progenitor cells (EPCs) were shown to have angiogenic potential
contributing to neovascularization. However, a clear definition of mouse EPCs by cell …

BACKGROUND: Circulating endothelial progenitor cells (EPCs) may play an important role
in the body's defense against atherosclerosis. Previous studies have shown an association …

Background—Exercise training (ET) has been shown to improve regional perfusion in
ischemic syndromes. This might be partially related to a regeneration of diseased …

Background—Transplantation of endothelial progenitor cells (EPCs) improves
vascularization and left ventricular function after experimental myocardial ischemia …

Aims Recent data suggest that the administration of bone marrow-derived stem cells
(BMSC) might improve myocardial perfusion and left ventricular (LV) function after acute …